DOCSLIB.ORG

DYNORPHIN-CONVERTING ENZYME in HUMAN CEREBROSPINAL a Negative Correlation Between Activity and Levels of Prodynorphin Derived Op

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DYNORPHIN-CONVERTING ENZYME in HUMAN CEREBROSPINAL a Negative Correlation Between Activity and Levels of Prodynorphin Derived Op See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/308329883 Dynorphin-converting enzyme in human cerebrospinal fluid. A negative correlation between activity and levels of prodynorphin derived opioid peptides Data · September 2016 CITATIONS READS 0 30 6 authors, including: Claes Post Henning Værøy Linköping University Akershus universitetssykehus 174 PUBLICATIONS 5,425 CITATIONS 65 PUBLICATIONS 1,763 CITATIONS SEE PROFILE SEE PROFILE Fred Nyberg Uppsala University 467 PUBLICATIONS 13,047 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: The impact of opioid peptides in body fluids View project Frondoside A, anti cancer agent View project All content following this page was uploaded by Henning Værøy on 20 September 2016. The user has requested enhancement of the downloaded file. s155 DYNORPHIN-CONVERTING ENZYME IN HUMAN CEREBROSPINAL FLUID. A negative correlation between activity and levels of prodynorphin derived opioid peptides. Madeleine ThSmwall, Susanne Schwarzmayr, Bela Almay *, Claes Post **, Henning VaerCy *** and Fred Nyberg. Dept. of Pharmaceutical Biosciences, Division of Pharmacology, University of Uppsala, P.O. Box 591, S-751 24 UPPSALA, Sweden.* Dept. of Neurology, University of Ume~, S-801 87 UMEA, Sweden.** Astra Draeo AB P.O. Box 34, S-221 20 LUND, Sweden.*** Dept. of Psychiatry, Gjcvik Fylkessykehus, N-2800 GJI~VIK, Norway. In this work we have studied the dynorphin convertase (DCE) in cerebrospinal fluid (CSF) collected from patients with different states of chronic pain. The assessment of the enzyme activity was accompanied with measurements of the CSF level of prodynorphin derived opioid peptides. In CSF from patients with fibromyalgia the DCE activity was found to be significantly decreased as compared to that of control samples. In contrast a significant increase was found for the level of immunoreactive dynorphin A. In CSF from patients with idiopathic pain a significant negative correlation between all prodynorphin derived peptides and DCE activity was observed. The results suggest a regulatory function on the peptide level of the dynorphin convertase. Table I Propertiesof CSF Dynorphin-convertingenzyme.(3) Previous studies have demonstrated the pretence of a specific convertase acting Mw ~40000 on prodynorphin derived opioid peptides Inhibited by PMSF and DFP, classifying DCE as a serine protease in human cerebrospinal fluid. The pH-optimum: -7.4 enzyme has a molecular weight of around Isoeletric point: -6.9 40 kdalton and was shown to hydrolyze Cleavage sites: Arg-Arg/Arg-Lys the substrate peptides at their paired basic Specificity: Dynorphin A Kin=t30 paM amino acid residues. In accordance with Specific activity: 2.4 mUImg enzyme protein its sensitivity towards protease inhibitors Dynorphin B Kin--160 l.tM as PMSF and DFP it was classified as a Specific activity: 0.4 mU/mg enzyme protein serine protease (table I). The CSF samples studied in this work were obtained by lumbar puncture from 25 different subjects with chronic pain, where 9 patients were diagnosed with idiopathic pain and 16 with fibromyalgia. Controls were 11 urological patients with conditions without pain. The frozen CSF sample (2 ml) was thawed and directly separated on a disposable reversed phase octadeca-silyl silica gel, SepPak, cartridge. Before use, the cartridge was successively washed with 5 ml methanol, 5 ml methanol containing 0.04 % trifluoroacetic acid (TFA) and 10 ml H20/0.04 % TFA. The samples were then applied onto the cartridges. After washing with 4 ml H20/0.04 % TFA and 20 % methanol/0.04 % TFA, elution was performed with 4 ml 100 % methanol containing 0.04 % TFA. The fractions were evaporated and subjected to tryptic treatment prior to analysis by radioimmunoassay (RIA) as described elsewhere (2). The converting activity was monitored by following the formation of Leu-enkephalin-Arg6 from synthetic dynorphin A. The incubations were performed in 50 mM Tris/l-lC1, pH 7.4 in Eppendorf tubes in a final volume of 50 lxl. In order to prevent further degradation of the product the protease inhibitors amastatin, captopril and phosphoramidon (inhibitors of aminopeptidase, angiotensin-converting enzyme and neutral endopeptidase EC.3.4.24.11, respectively) were added in a final concentration of 20 ~tM. The incubations were allowed to proceed for 120 rain at 37oc and the reactions were terminated by adding cold methanol. Samples were evaporated and the released product was quantified by RIA. The results showed that levels of DCE activity are significantly decreased in CSF collected from patients with fibromyalgia as compared to control samples (fig. la). Further, in a previous study (4) it was found that CSF levels of dynorphin A are significantly increased in fibromyalgia patients (fig. lb). It seems that in these patients the enzyme activity is lowered at the expense of increased peptide levels. In patients with idiopathic pain the activity of DCE was found to be elevated and the enzyme activity correlated negatively with the peptide concentration (fig. 2). S156 m A O i- < C 7: O ! C Control Flbromyalgla Control Flbromyelgla n=l 1 .=16 n=6 n=32 Fig. 1. a) Dynorphin-eonverting enzyme activity in CSF from patients with fibromyalgia, expressed as rate of formation of Leu-enk-Arg6 ( pmol/h*ml CSF) from dynorphin A ('t)<0.05) b) Dynorphin A levels in CSF from patients with fibromyalgia, (fmol/ml CSF). (*p<0.05) y = -2.164x ÷ 191.567, R-aqu-r'~d: .58 220 200 180 160 13._ (3- 140. t.l.l 120. 100. 80. 60 I 0 5 ~0 15 20 25 30 35 40 45-. 50 Fig.2. Regressionanalysis between levels of LEA-PP (fmol/ml) and DCE activity (pmol Leu-enk-Arg6/h*ml CSF). (1)<0.02, n=9) It appears from this study that in patients with fibromyalgia, a decrease in DCE activity is contrasted by an increase in the substrate peptide. These results combined with the negative correlation between prodynorphin derived peptides and DCE in CSF from patients with idiopathic pain may indicate a regulatory role of enzyme in pain processing pathways within the CNS. The present results suggest that the assessment of the CSF activity in the prodynorphin system (~cluding measurements of DCE) may have a clear potential in the differential diagnosis of chronic pain syndromes. A chaUange to future work would be to follow up these studies on a broader scale, also to include patients with other pain diagnosis. (This study was supported by the Swedish Medical Research Council, Grant No. 9459). Nyberg, F., Nordstrtm, K. and Terenius, L. Biochem. Biophys. Res. Commun. (1985), 131, 1069-1074. Silberring, J. and Nyberg, F. J. Biol. Chem. (1989), 264, 11082. 3. Demuth, H-U. and Nyberg, F. J. Enzyme Inhibition (1991), 4, 299-306. 4. VaerCy, H., Nyberg, F. and Terenius, L. Pain (1991), 46, 139-143. View publication stats.
Load more

Recommended publications
  • Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J
    Clinical Biochemistry xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Analytical performance of an immunoassay to measure proenkephalin ⁎ Leslie J. Donatoa, ,Jeffrey W. Meeusena, John C. Lieskea, Deborah Bergmannc, Andrea Sparwaßerc, Allan S. Jaffea,b a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States b Division of Cardiology, Mayo Clinic, Rochester, MN 55905, United States c Sphingotec GmbH, Hennigsdorf, Germany ARTICLE INFO ABSTRACT Keywords: Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature Biomarkers pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 Proenkephalin (PENK), a stable peptide formed concomitantly with mature enkephalins. Enkephalin Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich im- Pro-enkephalin munoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from penKid healthy individuals to establish a reference interval and in patients with varied levels of kidney function and Assay validation comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quanti- tation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days.
    [Show full text]
  • Identification of Β-Endorphins in the Pituitary Gland and Blood Plasma Of
    271 Identification of -endorphins in the pituitary gland and blood plasma of the common carp (Cyprinus carpio) E H van den Burg, J R Metz, R J Arends, B Devreese1, I Vandenberghe1, J Van Beeumen1, S E Wendelaar Bonga and G Flik Department of Animal Physiology, Faculty of Science, University of Nijmegen, Toernooiveld 1, 6525 ED Nijmegen, The Netherlands 1Laboratory of Protein Biochemistry and Protein Engineering, University of Gent, KL Ledeganckstraat 35, B9000 Gent, Belgium (Requests for offprints should be addressed to G Flik; Email: gertfl[email protected]) Abstract Carp -endorphin is posttranslationally modified by N-acetyl -endorphin(1–29) and these forms together N-terminal acetylation and C-terminal cleavage. These amounted to over 50% of total immunoreactivity. These processes determine the biological activity of the products were partially processed to N-acetyl - -endorphins. Forms of -endorphin were identified in endorphin(1–15) (30·8% of total immunoreactivity) and the pars intermedia and the pars distalis of the pituitary N-acetyl -endorphin(1–10) (3·1%) via two different gland of the common carp (Cyprinus carpio), as well as the cleavage pathways. The acetylated carp homologues of forms released in vitro and into the blood. After separation mammalian - and -endorphin were also found. and quantitation by high performance liquid chroma- N-acetyl -endorphin(1–15) and (1–29) and/or (1–33) tography (HPLC) coupled with radioimmunoassay, the were the major products to be released in vitro, and were -endorphin immunoreactive products were identified by the only acetylated -endorphins found in blood plasma, electrospray ionisation mass spectrometry and peptide although never together.
    [Show full text]
  • Antitumor Activity of Actinonin in Vitro and in Vivo
    Vol. 4, 171-176, January 1998 Clinical Cancer Research 171 Antitumor Activity of Actinonin in Vitro and in Vivo Yang Xu, Lawrence T. Lai, Janice L. Gabrilove, 8), mye!oid and monocytic cells, and most myeloblastic leuke- and David A. Scheinberg’ mias as well as on cells and tissues outside the hematopoietic system including fibroblasts, intestinal epithelium, renal tubular Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 epithelium, and synaptic membranes of the central nervous system (I ). APN occurs as a homodimer, and the molecule is a 150-kDa, transmembrane glycoprotein with an intracellular ABSTRACT amino terminus (1). F23, an antihuman CD13/APN mAb, is able Actinonin, an antibiotic and CD13/aminopeptidase N to completely block the active site of the enzyme (9). (APN) inhibitor, has been shown to be cytotoxic to tumor Bestatin, a CD 1 3/APN inhibitor, was examined in preclin- cell lines in vitro. We investigated the antiproliferative ef- ical and clinical studies; bestatin could inhibit lymph node fects of actinonin on human and murine leukemia and lym- metastasis of P388 leukemia in mice (10) and was used in phoma cells. Actinonin inhibited growth of NB4 and HL6O clinical trials in malignant skin tumors (1 1), in head and neck human cell lines and AKR mouse leukemia cells in vitro with cancer (12), in esophageal cancer (13), and in gynecologic an IC50 of about 2-S g/ml. The inhibitory effect on CD13- tumors (14). High doses of bestatin resulted in the significant positive cells was not blocked by pretreatment with the inhibition of preexisting experimental and spontaneous metas- anti-CD13/APN monoclonal antibody F23, which binds with tasis in mice (15).
    [Show full text]
  • Biased Signaling by Endogenous Opioid Peptides
    Biased signaling by endogenous opioid peptides Ivone Gomesa, Salvador Sierrab,1, Lindsay Lueptowc,1, Achla Guptaa,1, Shawn Goutyd, Elyssa B. Margolise, Brian M. Coxd, and Lakshmi A. Devia,2 aDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Physiology & Biophysics, Virginia Commonwealth University, Richmond, VA 23298; cSemel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095; dDepartment of Pharmacology & Molecular Therapeutics, Uniformed Services University, Bethesda MD 20814; and eDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA 94143 Edited by Susan G. Amara, National Institutes of Health, Bethesda, MD, and approved April 14, 2020 (received for review January 20, 2020) Opioids, such as morphine and fentanyl, are widely used for the possibility that endogenous opioid peptides could vary in this treatment of severe pain; however, prolonged treatment with manner as well (13). these drugs leads to the development of tolerance and can lead to For opioid receptors, studies showed that mice lacking opioid use disorder. The “Opioid Epidemic” has generated a drive β-arrestin2 exhibited enhanced and prolonged morphine-mediated for a deeper understanding of the fundamental signaling mecha- antinociception, and a reduction in side-effects, such as devel- nisms of opioid receptors. It is generally thought that the three opment of tolerance and acute constipation (15, 16). This led to types of opioid receptors (μ, δ, κ) are activated by endogenous studies examining whether μOR agonists exhibit biased signaling peptides derived from three different precursors: Proopiomelano- (17–20), and to the identification of agonists that preferentially cortin, proenkephalin, and prodynorphin.
    [Show full text]
  • The Role of Protein Convertases in Bigdynorphin and Dynorphin a Metabolic Pathway
    Université de Montréal The Role of Protein Convertases in Bigdynorphin and Dynorphin A Metabolic Pathway par ALBERTO RUIZ ORDUNA Département de biomédecine vétérinaire Faculté de médecine vétérinaire Mémoire présenté à la Faculté de médecine vétérinaire en vue de l’obtention du grade de maître ès sciences (M.Sc.) en sciences vétérinaires option pharmacologie Décembre, 2015 © Alberto Ruiz Orduna, 2015 Résumé Les dynorphines sont des neuropeptides importants avec un rôle central dans la nociception et l’atténuation de la douleur. De nombreux mécanismes régulent les concentrations de dynorphine endogènes, y compris la protéolyse. Les Proprotéines convertases (PC) sont largement exprimées dans le système nerveux central et clivent spécifiquement le C-terminale de couple acides aminés basiques, ou un résidu basique unique. Le contrôle protéolytique des concentrations endogènes de Big Dynorphine (BDyn) et dynorphine A (Dyn A) a un effet important sur la perception de la douleur et le rôle de PC reste à être déterminée. L'objectif de cette étude était de décrypter le rôle de PC1 et PC2 dans le contrôle protéolytique de BDyn et Dyn A avec l'aide de fractions cellulaires de la moelle épinière de type sauvage (WT), PC1 -/+ et PC2 -/+ de souris et par la spectrométrie de masse. Nos résultats démontrent clairement que PC1 et PC2 sont impliquées dans la protéolyse de BDyn et Dyn A avec un rôle plus significatif pour PC1. Le traitement en C-terminal de BDyn génère des fragments peptidiques spécifiques incluant dynorphine 1-19, dynorphine 1-13, dynorphine 1-11 et dynorphine 1-7 et Dyn A génère les fragments dynorphine 1-13, dynorphine 1-11 et dynorphine 1-7.
    [Show full text]
  • Five Decades of Research on Opioid Peptides: Current Knowledge and Unanswered Questions
    Molecular Pharmacology Fast Forward. Published on June 2, 2020 as DOI: 10.1124/mol.120.119388 This article has not been copyedited and formatted. The final version may differ from this version. File name: Opioid peptides v45 Date: 5/28/20 Review for Mol Pharm Special Issue celebrating 50 years of INRC Five decades of research on opioid peptides: Current knowledge and unanswered questions Lloyd D. Fricker1, Elyssa B. Margolis2, Ivone Gomes3, Lakshmi A. Devi3 1Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA; E-mail: [email protected] 2Department of Neurology, UCSF Weill Institute for Neurosciences, 675 Nelson Rising Lane, San Francisco, CA 94143, USA; E-mail: [email protected] 3Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, Annenberg Downloaded from Building, One Gustave L. Levy Place, New York, NY 10029, USA; E-mail: [email protected] Running Title: Opioid peptides molpharm.aspetjournals.org Contact info for corresponding author(s): Lloyd Fricker, Ph.D. Department of Molecular Pharmacology Albert Einstein College of Medicine 1300 Morris Park Ave Bronx, NY 10461 Office: 718-430-4225 FAX: 718-430-8922 at ASPET Journals on October 1, 2021 Email: [email protected] Footnotes: The writing of the manuscript was funded in part by NIH grants DA008863 and NS026880 (to LAD) and AA026609 (to EBM). List of nonstandard abbreviations: ACTH Adrenocorticotrophic hormone AgRP Agouti-related peptide (AgRP) α-MSH Alpha-melanocyte stimulating hormone CART Cocaine- and amphetamine-regulated transcript CLIP Corticotropin-like intermediate lobe peptide DAMGO D-Ala2, N-MePhe4, Gly-ol]-enkephalin DOR Delta opioid receptor DPDPE [D-Pen2,D- Pen5]-enkephalin KOR Kappa opioid receptor MOR Mu opioid receptor PDYN Prodynorphin PENK Proenkephalin PET Positron-emission tomography PNOC Pronociceptin POMC Proopiomelanocortin 1 Molecular Pharmacology Fast Forward.
    [Show full text]
  • Enkephalin After Peptidase Inhibition
    J Pharmacol Sci 106, 295 – 300 (2008)2 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Great Increase in Antinociceptive Potency of [Leu5]Enkephalin After Peptidase Inhibition Kazuhito Akahori1, Kenya Kosaka1, Xing Lu Jin1, Yoshiharu Arai1, Masanobu Yoshikawa1, Hiroyuki Kobayashi1, and Tetsuo Oka1,* 1Department of Clinical Pharmacology, School of Medicine, Tokai University, Isehara 259-1143, Japan Received August 9, 2007; Accepted December 19, 2007 Abstract. Previous in vitro studies have shown that the degradation of [Leu5]enkephalin during incubation with cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors: amastatin, captopril, and phosphoramidon. The present in vivo study shows that the inhibitory effect of [Leu5]enkephalin administered intra-third-ventricularly on the tail-flick response was increased more than 500-fold by the intra-third-ventricular pretreatment with the three peptidase inhibitors. The antinociceptive effect produced by the [Leu5]enkephalin in rats pretreated with any combination of two peptidase inhibitors was significantly smaller than that in rats pretreated with the three peptidase inhibitors, indicating that any residual single peptidase could inactivate significant amounts of the [Leu5]enkephalin. The present data, together with those obtained from previous studies, clearly demonstrate that amastatin-, captopril-, and phosphoramidon-sensitive enzymes play important roles in the inactivation of short endogenous opioid
    [Show full text]
  • Distribution of Prodynorphin Mrna and Its Interaction with the NPY System in the Mouse Brain Neuropeptides 40 (2): 115-123, 2006
    Lin et al.: Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain Neuropeptides 40 (2): 115-123, 2006 Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain Shu Lina, Dana Boeya, Nicola Leea, Christoph Schwarzerb, Amanda Sainsburya, Herbert Herzoga, a Neurobiology Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australiab Department of Pharmacology, Medical University of Innsbruck, Peter- Mayr-Strasse 1a, 6020 Innsbruck, Austria Abstract Using radioactive in situ hybridisation, the distribution of prodynorphin mRNA in the brains of C57Bl/6 mice was systemically investigated, and double-labelling in situ hybridisation was used to determine the extent to which neuropeptide Y (NPY) and prodynorphin mRNAs were co-expressed. Our results demonstrate that prodynorphin mRNA expression in the mouse brain is localised at specific subregions of the olfactory bulb, cortex, hippocampus, amygdala, basal ganglia, thalamus, hypothalamus, mesencephalon and myelencephalon. Among the regions displaying the most intense labelling were the olfactory tubercle, lateral septum (LS), caudate putamen (Cpu), central amygdaloid nucleus (Ce), paraventricular hypothalamic nucleus (PVN), supraoptic nucleus (SO), lateral hypothalamic area (LHA), ventromedial hypothalamic nucleus (VMH), lateral reticular nucleus (LRt) and solitary tract nucleus (NTS). In the arcuate nucleus of the hypothalamus (Arc), double- labelling in situ hybridisation revealed that prodynorphin expressing neurons also contained NPY mRNA, with a co-localisation rate of approximately 88% in the lateral part of the Arc, and 79% in the dorsal part of the Arc, respectively, suggesting potential overlapping functions of these two neurotransmitters in feeding type behaviour.
    [Show full text]
  • New Trends in the Development of Opioid Peptide Analogues As Advanced Remedies for Pain Relief
    Current Topics in Medicinal Chemistry 2004, 4, 19-38 19 New Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief Luca Gentilucci* Dipartimento di Chimica “G. Ciamician”, via Selmi 2, Università degli Studi di Bologna, 40126- Bologna, Italy Abstract: The search for new peptides to be used as analgesics in place of morphine has been mainly directed to develop peptide analogues or peptidomimetics having higher biological stability and receptor selectivity. Indeed, most of the alkaloid opioid counterindications are due to the scarce stability and the contemporary activation of different receptor types. However, the development of several extremely stable and selective peptide ligands for the different opioid receptors, and the recent discovery of the m-receptor selective endomorphins, rendered this search less fundamental. In recent years, other opioid peptide properties have been investigated in the search for new pharmacological tools. The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and to remain metabolically stable in order to produce the desired effect. This review deals with the recent investigations on peptide bioavailability, in particular barrier penetration and resistance against enzymatic degradation; with the development of peptides having activity at different receptors; with chimeric peptides, with propeptides, and with non-conventional peptides, lacking basic pharmacophoric features. Key Words. Opioid peptide analogues; opioid receptors; pain; antinociception; peptide stability; bioavailability. INTRODUCTION. OPIOID PEPTIDES, RECEPTORS, receptor interaction by structure-function studies of AND PAIN recombinant receptors and chimera receptors [7,8]. Experiments performed on mutant mice gave new The endogenous opioid peptides have been studied information about the mode of action of opioids, receptor extensively since their discovery aiming to develop effective heterogeneity and interactions [9].
    [Show full text]
  • Structural Basis for Multifunctional Roles of Mammalian Aminopeptidase N
    Structural basis for multifunctional roles of mammalian aminopeptidase N Lang Chen, Yi-Lun Lin, Guiqing Peng, and Fang Li1 Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455 Edited by Ralph S. Baric, University of North Carolina, Chapel Hill, NC, and accepted by the Editorial Board September 21, 2012 (received for review June 13, 2012) Mammalian aminopeptidase N (APN) plays multifunctional roles in sensation and mood regulation by catalyzing the metabolism of many physiological processes, including peptide metabolism, cell neuropeptides that process sensory information. One of these motility and adhesion, and coronavirus entry. Here we determined neuropeptides is enkephalin, which binds to opioid receptors and crystal structures of porcine APN at 1.85 Å resolution and its com- has pain-relief and mood-regulating effects (9). APN degrades plexes with a peptide substrate and a variety of inhibitors. APN is and shortens the in vivo life of enkephalin, and hence enhances a cell surface-anchored and seahorse-shaped zinc-aminopeptidase pain sensation and regulates mood. Second, APN is involved in that forms head-to-head dimers. Captured in a catalytically active blood pressure regulation. APN degrades vasoconstrictive peptide state, these structures of APN illustrate a detailed catalytic mech- angiotensin-III, causing vasodilation and lowered blood pressure anism for its aminopeptidase activity. The active site and peptide- (10). An endogenous APN inhibitor, substance P, blocks both binding channel of APN reside in cavities with wide openings, the enkephalin-dependent and angiotensin-dependent pathways allowing easy access to peptides. The cavities can potentially open (11, 12). Third, APN is overexpressed on the cell surfaces of up further to bind the exposed N terminus of proteins.
    [Show full text]
  • Big Dynorphin, a Prodynorphin-Derived Peptide Produces NMDA Receptor-Mediated Effects on Memory, Anxiolytic-Like and Locomotor Behavior in Mice
    Neuropsychopharmacology (2006) 31, 1928–1937 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Big Dynorphin, a Prodynorphin-Derived Peptide Produces NMDA Receptor-Mediated Effects on Memory, Anxiolytic-Like and Locomotor Behavior in Mice ,1,2 1 2 1 2 Alexander Kuzmin* , Nather Madjid , Lars Terenius , Sven Ove Ogren and Georgy Bakalkin 1Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden; 2Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden Effects of big dynorphin (Big Dyn), a prodynorphin-derived peptide consisting of dynorphin A (Dyn A) and dynorphin B (Dyn B) on memory function, anxiety, and locomotor activity were studied in mice and compared to those of Dyn A and Dyn B. All peptides administered i.c.v. increased step-through latency in the passive avoidance test with the maximum effective doses of 2.5, 0.005, and 0.7 nmol/animal, respectively. Effects of Big Dyn were inhibited by MK 801 (0.1 mg/kg), an NMDA ion-channel blocker whereas those of dynorphins A and B were blocked by the k-opioid antagonist nor-binaltorphimine (6 mg/kg). Big Dyn (2.5 nmol) enhanced locomotor activity in the open field test and induced anxiolytic-like behavior both effects blocked by MK 801. No changes in locomotor activity and no signs of anxiolytic-like behavior were produced by dynorphins A and B. Big Dyn (2.5 nmol) increased time spent in the open branches of the elevated plus maze apparatus with no changes in general locomotion. Whereas dynorphins A and B (i.c.v., 0.05 and 7 nmol/animal, respectively) produced analgesia in the hot-plate test Big Dyn did not.
    [Show full text]
  • Specific Regions of the Rat Brain
    Proc. Nad. Acad. Sci. USA Vol. 81, pp. 6886-6889, November 1984 Neurobiology Differential processing of prodynorphin and proenkephalin in specific regions of the rat brain (dynorphins/neo-endorphins/[Leulenkephalin/[Metlenkephalin-Arg6-Gly7_Leu'/rat brain nuclei) NADAV ZAMIR*, ECKARD WEBERt, MIKLOS PALKOVITS*, AND MICHAEL BROWNSTEIN* *Laboratory of Cell Biology, National Institute of Mental Health, Bethesda, MD 20205; and tNancy Pritzker Laboratory of Behavioral Neurochemistry, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 Communicated by Seymour S. Kety, July 10, 1984 ABSTRACT Prodynorphin-derived peptides [dynorphin technique, from 300-,um thick frozen coronal sections cut in A (Dyn A)-(1-17), Dyn A-(1-8), Dyn B, a-neo-endorphin, and a cryostat at -10°C (21). Tissue samples were placed in Ep- (3-neo-endorphin] and proenkephalin-derived peptides pendorf tubes containing 200 M1 of0.1 M HC1 and transferred {[Leu]enkephalin ([Leu]Enk) and [Metlenkephalin-Arg6-Gly7- to a boiling water bath for 10 min. Samples were chilled in Leu8 ([Met]Enk-Arg-Gly-Leu)} in selected brain areas of the ice and then homogenized by sonication, and 20-,u aliquots rat were measured by specific radioimmunoassays. We report of the homogenates were removed for protein determination here that different regions of rat brain contain strikingly dif- (22). The extracts were centrifuged at 2000 x g for 10 min at ferent proportions of the prodynorphin and proenkephalin-de- 4°C. The supernatants were transferred to 12 x 75 mm poly- rived peptides. There is a molar excess of a-neo-endorphin- propylene or polystyrene tubes (the latter for RIAs of derived peptides over Dyn B and Dyn A-derived peptides in [Leu]Enk and [Met]Enk-Arg-Gly-Leu) and evaporated to many brain areas.
    [Show full text]